Login to Your Account



Avastin Wallops Q2 Estimates; Genentech Cracks Billion Mark

By Randall Osborne


Friday, July 9, 2004
Analysts had set the expectations bar high, but Genentech Inc. vaulted over it - again - with a second-quarter earnings report showing product sales of $913.4 million, a 42 percent increase over the same period last year, powered largely by sales of the colorectal wonder-drug Avastin. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription